Medications in the first trimester of pregnancy: most common exposures and critical gaps in understanding fetal risk
ABSTRACT
Purpose
To determine which medications are most commonly used by women in the first trimester of pregnancy and identify the critical gaps in information about fetal risk for those medications.
Methods
Self‐reported first‐trimester medication use was assessed among women delivering liveborn infants without birth defects and serving as control mothers in two large case–control studies of major birth defects. The Teratology Information System (TERIS) expert Advisory Board ratings of quality and quantity of data available to assess fetal risk were reviewed to identify information gaps.
Results
Responses from 5381 mothers identified 54 different medication components used in the first trimester by at least 0.5% of pregnant women, including 31 prescription and 23 over‐the‐counter medications. The most commonly used prescription medication components reported were progestins from oral contraceptives, amoxicillin, progesterone, albuterol, promethazine, and estrogenic compounds. The most commonly used over‐the‐counter medication components reported were acetaminophen, ibuprofen, docusate, pseudoephedrine, aspirin, and naproxen. Among the 54 most commonly used medications, only two had “Good to Excellent” data available to assess teratogenic risk in humans, based on the TERIS review.
Conclusions
For most medications commonly used in pregnancy, there are insufficient data available to characterize the fetal risk fully, limiting the opportunity for informed clinical decisions about the best management of acute and chronic disorders during pregnancy. Future research efforts should be directed at these critical knowledge gaps. Copyright © 2013 John Wiley & Sons, Ltd.
Number of times cited: 18
- Marlene Sinclair, B.M. Lagan, Helen Dolk and Julie E. M. McCullough, An assessment of pregnant women's knowledge and use of the Internet for medication safety information and purchase, Journal of Advanced Nursing, 74, 1, (137-147), (2017).
- Molly M. Lynch, Linda B. Squiers, Katherine M. Kosa, Suzanne Dolina, Jennifer Gard Read, Cheryl S. Broussard, Meghan T. Frey, Kara N. Polen, Jennifer N. Lind, Suzanne M. Gilboa and Janis Biermann, Making Decisions About Medication Use During Pregnancy: Implications for Communication Strategies, Maternal and Child Health Journal, 22, 1, (92), (2018).
- Elyse Olshen Kharbanda, Gabriela Vazquez‐Benitez, Paul A. Romitti, Allison L. Naleway, T. Craig Cheetham, Heather S. Lipkind, Shanthi Sivanandam, Nicola P. Klein, Grace M. Lee, Michael L. Jackson, Simon J. Hambidge, Avalow Olsen, Natalie McCarthy, Frank DeStefano and James D. Nordin, Identifying birth defects in automated data sources in the Vaccine Safety Datalink, Pharmacoepidemiology and Drug Safety, 26, 4, (412-420), (2017).
- J Scaffidi, BW Mol and JA Keelan, The pregnant women as a drug orphan: a global survey of registered clinical trials of pharmacological interventions in pregnancy, BJOG: An International Journal of Obstetrics & Gynaecology, 124, 1, (132-140), (2016).
- Kate Gelperin, Hoda Hammad, Kira Leishear, Steven T. Bird, Lockwood Taylor, Christian Hampp and Leyla Sahin, A systematic review of pregnancy exposure registries: examination of protocol‐specified pregnancy outcomes, target sample size, and comparator selection, Pharmacoepidemiology and Drug Safety, 26, 2, (208-214), (2016).
- Elizabeth C. Ailes, Regina M. Simeone, April L. Dawson, Emily E. Petersen and Suzanne M. Gilboa, Using insurance claims data to identify and estimate critical periods in pregnancy: An application to antidepressants, Birth Defects Research Part A: Clinical and Molecular Teratology, 106, 11, (927-934), (2016).
- Susan M. Sinclair, Richard K. Miller, Christina Chambers and Elizabeth M Cooper, Medication Safety During Pregnancy: Improving Evidence‐Based Practice, Journal of Midwifery & Women's Health, 61, 1, (52-67), (2016).
- Sherif Eltonsy, Brigitte Martin, Ema Ferreira and Lucie Blais, Systematic procedure for the classification of proven and potential teratogens for use in research, Birth Defects Research Part A: Clinical and Molecular Teratology, 106, 4, (285-297), (2016).
- AA Mitchell, Research challenges for drug‐induced birth defects, Clinical Pharmacology & Therapeutics, 100, 1, (26-28), (2016).
- Henrike Hoeke, Stefan Roeder, Thilo Bertsche, Michael Borte, Martin Bergen and Dirk K. Wissenbach, Assessment of maternal drug intake by urinary bio monitoring during pregnancy and postpartally until the third perinatal year, Pharmacoepidemiology and Drug Safety, 25, 4, (431-437), (2015).
- Craig Hansen, Susan E. Andrade, Heather Freiman, Sascha Dublin, Katie Haffenreffer, William O. Cooper, T. Craig Cheetham, Sengwee Toh, De‐Kun Li, Marsha A. Raebel, Jennifer L. Kuntz, Nancy Perrin, A. Gabriela Rosales, Shelley Carter, Pamala A. Pawloski, Elizabeth M. Maloney, David J. Graham, Leyla Sahin, Pamela E. Scott, John Yap and Robert Davis, Trimethoprim–sulfonamide use during the first trimester of pregnancy and the risk of congenital anomalies, Pharmacoepidemiology and Drug Safety, 25, 2, (170-178), (2015).
- Craig Hansen, Julia D Interrante, Elizabeth C Ailes, Meghan T Frey, Cheryl S Broussard, Valerie J Godoshian, Courtney Lewis, Kara ND Polen, Amanda P Garcia and Suzanne M Gilboa, Assessment of YouTube videos as a source of information on medication use in pregnancy, Pharmacoepidemiology and Drug Safety, 25, 1, (35-44), (2015).
- Carol Louik, Stephen Kerr, Katherine E. Kelley and Allen A. Mitchell, Increasing use of ADHD medications in pregnancy, Pharmacoepidemiology and Drug Safety, 24, 2, (218-220), (2015).
- Anne S. Ersbøll, Mette Hedegaard, Peter Damm, Marianne Johansen, Ann Tabor and Hanne K. Hegaard, Changes in the pattern of paracetamol use in the periconception period in a Danish cohort, Acta Obstetricia et Gynecologica Scandinavica, 94, 8, (898-903), (2015).
- Laurence Fays, Karen Van Malderen, Karen De Smet, Javier Sawchik, Veerle Verlinden, Jamila Hamdani, Jean‐Michel Dogné and Bernard Dan, Use of paracetamol during pregnancy and child neurological development, Developmental Medicine & Child Neurology, 57, 8, (718-724), (2015).
- Nancy A Dreyer, Stella CF Blackburn, Shahrul Mt-Isa, Jonathan L Richardson, Simon Thomas, Maja Laursen, Priscilla Zetstra-van der Woude, Anna Jamry-Dziurla, Valerie Hliva, Alison Bourke and Lolkje de Jong-van den Berg, Direct-to-Patient Research: Piloting a New Approach to Understanding Drug Safety During Pregnancy, JMIR Public Health and Surveillance, 1, 2, (e22), (2015).
- , Fetal risk for first-trimester medications often unknown, Reactions Weekly, 1465, 1, (4), (2013).
- , Fetal risk for first-trimester medications often unknown, PharmacoEconomics & Outcomes News, 685, 1, (8), (2013).
